Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia

NCT06389266 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT06389266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06389266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia
Lead sponsor
Vanderbilt University Medical Center
Phase
Not applicable
Overall status
Completed
Start date
June 15, 2023
Completion date
September 22, 2025
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nicotine dependence, schizophrenia